Lymphomas and Chronic Lymphocytic Leukemia

CCO&rsquo s expert faculty review and share their expert perspectives on key findings in lymphomas and chronic lymphocytic leukemia presented at the 2019 ASH annual meeting.

Share

Program Content

Activities

  • ASH 2019: CLL/Lymphomas
    My Take on Key Studies in CLL and Lymphomas From ASH 2019
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 23, 2020

    Expires: January 21, 2021

Activities

Frontline AVO in CLL
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab Combination Therapy in Previously Untreated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2019

Expires: December 07, 2020

Phase II CAPTIVATE Study
Phase II CAPTIVATE Trial of First-line Ibrutinib Plus Venetoclax in CLL/SLL: MRD Cohort Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

ELEVATE TN
ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

Mosunetuzumab in R/R NHL
Phase I/Ib Study of Mosunetuzumab in Heavily Pretreated Patients With R/R B-Cell Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2019

Expires: December 10, 2020

TRANSCEND NHL 001
TRANSCEND NHL 001: Phase I Study of Lisocabtagene Maraleucel in R/R LBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2019

VEN+IBR in High-Risk CLL
Venetoclax and Ibrutinib Combination Therapy for Treatment-Naive High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

KTE-X19 in R/R MCL
Phase II ZUMA-2 Trial of KTE-X19 CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

Real-world Axi-Cel Data
Postmarketing Outcomes of CD19-Directed CAR T-Cell Agent Axicabtagene Ciloleucel for Treatment of Large B-Cell Lymphoma in the United States
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

TRANSCEND NHL 001: PROs With Liso-Cel
TRANSCEND NHL 001: Patient-Reported Outcomes With Liso-Cel in Patients With Relapsed/Refractory Aggressive B-Cell NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

LOXO-305 in CLL/B-Cell NHL
BRUIN: First-in-Human Phase I Trial Investigating Non-Covalent BTK Inhibitor LOXO-305 in Pretreated B-Cell Malignancies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

TRANSCEND CLL 004 Updates
Phase I/II TRANSCEND CLL 004: Updated Results of Lisocabtagene Maraleucel in Patients With Relapsed/Refractory CLL or SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

Faculty

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company